Henry Schein (HSIC) Q4 2025 earnings review
Cyber Hangover Clears: Accelerating Growth and a Clean Slate for the New CEO
Henry Schein decisively closed the chapter on its late-2023 cyber incident, delivering 7.7% YoY revenue growth in Q4—its highest in 15 quarters. The volume rebound translated well to the bottom line, with Non-GAAP EPS jumping 13% to $1.34. The recovery was broad-based, highlighted by a sharp reversal in Global Equipment sales and continued momentum in high-margin Specialty and Technology segments. With long-time CEO Stanley Bergman handing the reins to Fred Lowery next week, the incoming leadership inherits a stabilized operation, an active KKR-backed cost-efficiency program, and solid 2026 guidance projecting another year of record earnings.
🐂 Bull Case
After struggling with tariff uncertainty and deferred installations earlier in the year, Global Equipment sales surged 12.2% (9.1% constant currency) in Q4, signaling renewed capital investment by dental practices.
The BOLD+1 strategic plan is working. The high-margin Global Specialty Products (+14.6%) and Global Technology (+8.4%) segments are materially outgrowing the core distribution business, fundamentally improving the company's profit profile.
🐻 Bear Case
The gap between adjusted and actual earnings remains massive. In 2025, GAAP Net Income was $398M, while Non-GAAP was $605M. Chronic exclusions for restructuring, KKR advisory fees, and acquisition amortization erode actual shareholder returns.
Stanley Bergman has led the company for decades. While Fred Lowery's appointment brings fresh perspective, transitioning leadership in a complex, global distribution network carries inherent execution risk.
⚖️ Verdict: 🟢
Bullish. The core business has fully normalized post-cyberattack, high-margin segments are accelerating, and aggressive share repurchases ($850M in 2025) provide a strong floor for EPS growth moving into 2026.
Key Themes
Global Dental Equipment Sharp Rebound
Reversing the weakness seen in the first half of the year (where US Equipment sales declined due to tariff-related deferrals), Global Equipment sales grew a robust 12.2% YoY in Q4. Management noted particularly strong growth in the U.S., Germany, Brazil, Canada, and Australia. This indicates that dental practices have absorbed macro uncertainties and are back to investing in large capital items.
Cloud Software Upgrades Driving Technology Segment
The Global Technology group delivered 8.4% reported growth (7.6% constant currency) in Q4. This growth is accelerating due to the rapid adoption of cloud-based practice management software, primarily Dentrix Ascend and Dentally, alongside newly launched revenue cycle management solutions. This SaaS transition improves revenue visibility and margins.
Aggressive Capital Returns & KKR Value Creation
Henry Schein aggressively utilized its balance sheet in 2025, buying back 12.1 million shares for $850 million (roughly 10% of outstanding shares). Combined with KKR's strategic input on a $200M+ run-rate operating improvement program (targeting centralization and procurement), the company is pulling multiple levers to guarantee EPS growth even if top-line markets soften.
Persistent 'One-Time' Restructuring Costs
A major concern remains the structural reliance on non-GAAP adjustments. In 2025, the company excluded $105M in restructuring costs and $36M in 'shareholder advisory matters and select value creation consulting costs.' Investors should question whether the KKR-led efficiency program is truly accretive if the consulting and implementation costs are chronically excluded from the bottom line.
Macro: Ongoing Tariff and Supply Chain Pressures
While equipment sales rebounded, the distribution business continues to navigate a complex macro environment. Tariffs heavily impacted the cost of goods (particularly gloves and consumables sourced from Asia) throughout 2025. While the company has mitigated this via private-label switching and supplier negotiations, any escalation in global trade tensions in 2026 could quickly compress gross margins.
Other KPIs
Accelerating. Up 7.8% YoY from $270 million in 24Q4. For the full year, Adjusted EBITDA reached $1.101 billion, up 3.8% YoY, reflecting the successful flow-through of higher volumes and early benefits from the restructuring programs.
Accelerating. Surged 14.6% YoY (11.1% in constant currency). This segment, which houses dental implants and endodontics, is the primary driver of Henry Schein's margin expansion strategy. The double-digit growth proves the company is successfully capturing market share in high-acuity procedures.
Stable. The company retired 2.8 million shares at an average price of $71.10. For the full year, share count reduction contributed significantly to the 4.9% growth in Non-GAAP EPS. $780 million remains authorized for future buybacks.
Guidance
Accelerating. The midpoint of $5.30 implies a 6.6% YoY growth compared to 2025's $4.97. This signals management's confidence that restructuring savings and KKR-led initiatives will increasingly drop to the bottom line.
Stable. Represents a steady continuation of 2025's 4.0% total growth. This indicates that while the massive post-cyber rebound comps are over, the underlying dental and medical end-markets remain healthy and the company expects to hold its market share gains.
Stable. Consistent with 2025's actual growth, suggesting operating margins will remain relatively steady as gross margin improvements from Specialty/Tech mix shifts are offset by investments in the new e-commerce platform and inflation.
Key Questions
Equipment Momentum Sustainability
Global equipment sales surged 12% this quarter after a stagnant first half. How much of this was pent-up demand from delayed Q2/Q3 orders versus a structural improvement in dentist capital spending sentiment?
Value Creation Timeline and Costs
With another $12M spent on 'value creation consulting' in Q4 alone, when will these KKR-led initiatives transition from an ongoing non-GAAP add-back expense to pure organic operational leverage?
CEO Transition Priorities
As Fred Lowery takes over as CEO, what are his immediate first 100-day priorities, specifically regarding the ongoing BOLD+1 strategic shift and the pace of M&A versus share repurchases?
Distribution Gross Margins
Has the pricing pressure on gloves and basic consumables completely stabilized, or are you still utilizing targeted promotional pricing to defend market share in North America?